The earnings call highlights growth across pharmacy and international segments, along with successful cost management initiatives and improved free cash flow. However, these positives are balanced by challenges in retail sales, decreased adjusted EPS, and market difficulties.

Company Guidance

In the recent Walgreens Boots Alliance earnings call for the first quarter of fiscal year 2025, guidance highlighted several key metrics and strategic moves. The company reported a 6.9% increase in sales on a constant currency basis, with adjusted EPS of $0.51, albeit a 23% decline year-over-year due to prior year sale leaseback gains and lower Syncora equity income. The US pharmacy sector saw a 12.7% rise in comparable sales, driven by brand inflation and script volume, while retail sales declined due to a weaker cough, cold, and flu season. The company is addressing these challenges through a store footprint optimization program, expecting to close about 450 stores by the end of the year, with a projected $100 million AOI benefit. Efforts to improve pharmacy operations include enhanced micro-fulfillment centers, currently serving approximately 4,800 stores, which have increased shipped volumes by 23% and reduced costs by 13%. Walgreens continues to focus on employee scheduling optimization and procurement improvements with Syncora to stabilize costs. Despite a challenging retail environment, the company reaffirms its adjusted EPS guidance of $1.40 to $1.80 for fiscal 2025, citing progress in contractual negotiations and operational efficiencies.

Increased Sales Across Segments

Sales increased 6.9% on a constant currency basis with growth across all segments. Pharmacy comp sales increased 12.7% driven by brand inflation and script volume.

Successful Store Closure Strategy

The footprint optimization program is exceeding historical script retention rates, with the company on track to close nearly 500 locations during fiscal year 2025.

Improved Free Cash Flow

Free cash flow improved year-over-year, benefiting from decreased capital expenditures and higher adjusted operating income, excluding sale leaseback impacts.

International and Healthcare Segment Growth

Boots UK comp retail sales increased 8.1%, and US Healthcare sales grew by 12% compared to the prior year quarter.

Walgreens Boots Alliance (WBA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

WBA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 09, 2025	2025 (Q4)	0.24 / -	0.39	―	―	―
Apr 08, 2025	2025 (Q2)	0.54 / 0.63	1.2	-47.50% (-0.57)	―	―
Mar 06, 2025	2025 (Q3)	0.33 / 0.38	0.63	-39.68% (-0.25)	―	―
Jan 10, 2025	2025 (Q1)	0.38 / 0.51	0.66	-22.73% (-0.15)
Oct 15, 2024	2024 (Q4)	0.36 / 0.39	0.67	-41.79% (-0.28)
Jun 27, 2024	2024 (Q3)	0.68 / 0.63	1	-37.00% (-0.37)
Mar 28, 2024	2024 (Q2)	0.82 / 1.20	1.16	3.45% (+0.04)
Jan 04, 2024	2024 (Q1)	0.62 / 0.66	1.16	-43.10% (-0.50)
Oct 12, 2023	2023 (Q4)	0.69 / 0.67	0.8	-16.25% (-0.13)
Jun 27, 2023	2023 (Q3)	1.07 / 1.00	0.96	4.17% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

WBA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 08, 2025	$10.71	$10.59	-1.12%
Mar 06, 2025	$10.75	$10.60	-1.40%
Jan 10, 2025	$9.22	$11.76	+27.55%
Oct 15, 2024	$8.73	$10.11	+15.81%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.